Oncothyreon Inc (ONTY) 1.21 $ONTY
Oncothyreon Announces Corporate Name Change to Cascadian Therapeutics (NASDAQ: CASC)
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced that the Company is changing its name to Cascadian Therapeutics, Inc. and will trade on the NASDAQ Global Select Market under the new ticker symbol "CASC," effective at market open on June 9, 2016.
CASC: 1.12 (-0.03), ONTY: 1.21 (+0.02)
Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 in HER2+ Metastatic Breast Cancer at ASCO
GlobeNewswire - Sun Jun 05, 8:00AM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced the presentation of clinical data on its lead product candidate, ONT-380, at the 52 Annual Meeting of the American Society of Clinical Oncology (ASCO). ONT-380 is a highly selective small molecule HER2 inhibitor being developed in combination to treat HER2+ advanced or metastatic breast cancer.
ONTY: 1.21 (+0.02)
Oncothyreon reports 1Q loss
Automated Insights - Mon May 09, 3:19PM CDT
SEATTLE (AP) _ Oncothyreon Inc. (ONTY) on Monday reported a loss of $12.9 million in its first quarter.
ONTY: 1.21 (+0.02)
Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update
GlobeNewswire - Mon May 09, 3:02PM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the quarter ended March 31, 2016.
ONTY: 1.21 (+0.02)
Oncothyreon (ONTY) Catches Eye: Stock Moves 11.6% Higher
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 3:31AM CDT
Oncothyreon Inc (ONTY) shares rose almost 12% in the last trading session.
ANIK: 47.94 (+0.70), ONTY: 1.21 (+0.02)
Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:00AM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced the presentation of data highlighting the preclinical development of orally bioavailable, potent and selective checkpoint kinase 1 (Chk1) inhibitors. Results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.
ONTY: 1.21 (+0.02)
Oncothyreon Appoints Scott D. Myers Chief Executive Officer
GlobeNewswire - Tue Mar 29, 7:00AM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products to improve the lives and outcomes of patients with cancer, today announced the appointment of Scott D. Myers as President, Chief Executive Officer and a member of the Board of Directors, effective April 4, 2016.
ONTY: 1.21 (+0.02)
Endometrial Cancer - Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66589/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Endometrial Cancer Overview - Therapeutics Development - Pipeline Products for Endometrial Cancer - Overview - Pipeline Products for Endometrial Cancer - Comparative Analysis - Endometrial Cancer - Therapeutics under Development by Companies - Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes - Endometrial Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Endometrial Cancer - Products under Development by Companies - Endometrial Cancer - Products under Investigation by Universities/Institutes - Endometrial Cancer - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BeiGene(Beijing) Co.,Ltd - Boehringer Ingelheim GmbH - Cellceutix Corporation - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Pharmsynthez - Puma Biotechnology, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/s6...ndometrial
INCY: 80.81 (-0.29), IMGN: 2.80 (-0.01), ARQL: 1.40 (-0.08), LLY: 77.23 (-0.52), GSK: 42.98 (-0.48), ONTY: 1.21 (+0.02), MDVN: 80.93 (+0.37), MRK: 62.90 (+0.11), AZN: 32.60 (-0.21), AVEO: 0.91 (-0.02), GALE: 0.39 (-0.01), PBYI: 58.71 (-0.44), NVS: 78.27 (-0.50), KPTI: 11.10 (+1.15), XLRN: 30.25 (+0.24), EXEL: 11.35 (+0.20)
Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. as Interim CEO and Expands Board With Additions of Mark Lampert and Gwen Fyfe, M.D.
GlobeNewswire - Mon Jan 11, 7:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced that Robert L. Kirkman, M.D., has retired as president and CEO and as a member of the Board of Directors, effective January 11, 2016. Oncothyreon's Board of Directors has appointed Christopher S. Henney, Ph.D., D.Sc., the company's chairman, to serve as interim CEO while the company conducts a comprehensive search for a new CEO.
ONTY: 1.21 (+0.02)
Is Oncothyreon (ONTY) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Thu Dec 31, 7:31AM CST
Oncothyreon is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
ONTY: 1.21 (+0.02)
Where Investors Are Going - Complementary Research on Crocs, Oncothyreon, Nimble Storage and Rexnord
ACCESSWIRE - Mon Dec 21, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Crocs Inc. (NASDAQ: CROX), Oncothyreon Inc. (NASDAQ: ONTY), Nimble Storage Inc. (NYSE: NMBL) and Rexnord Corp. (NYSE: RXN). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CROX: 8.49 (-0.15), NMBL: 8.18 (-0.04), RXN: 21.74 (-0.37), ONTY: 1.21 (+0.02)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
BusinessWire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 0.34 (unch), TSRO: 84.35 (-0.34), CTMX: 11.72 (-0.01), NK: 8.04 (-0.05), CNCR: 24.03 (-0.05), SRNE: 6.76 (+0.10), XNCR: 21.43 (+0.30), ONTY: 1.21 (+0.02), CYAD: 22.48 (+0.48)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Fri Dec 11, 8:51AM CST
NEW YORK, NY / ACCESSWIRE / December 11, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
EYES: 3.36 (+0.01), PBMD: 0.85 (-0.02), CGEN: 7.05 (+0.02), ONTY: 1.21 (+0.02)
Timing is Crucial, Upside Analysis - Analyst Reports on YRC Worldwide, Crocs, Oncothyreon and Nimble Storage
ACCESSWIRE - Thu Dec 10, 9:55AM CST
NEW YORK, NY / ACCESSWIRE / December 10, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: YRC Worldwide Inc. (NASDAQ: YRCW), Crocs Inc. (NASDAQ: CROX), Oncothyreon Inc. (NASDAQ: ONTY) and Nimble Storage Inc. (NYSE: NMBL). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CROX: 8.49 (-0.15), NMBL: 8.18 (-0.04), ONTY: 1.21 (+0.02), YRCW: 11.58 (-0.01)
Oncothyreon Inc (USA) Plunges on Confusing Data
Brian Orelli, The Motley Fool - Motley Fool - Wed Dec 09, 12:58PM CST
What: Oncothyreon is down 30% at 1:30 p.m. EST after announcing updated data from its ongoing trials testing ONT-380 in patients with breast cancer yesterday. So what: From the stock move, you'd think the data was clearly negative, but it may...
ONTY: 1.21 (+0.02)
Global Brain Cancer Therapeutics Pipeline Review, H2 2015
M2 - Wed Dec 09, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wpxrw/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - AngioChem Inc. - Arrien Pharmaceuticals, LLC - BeiGene(Beijing) Co.,Ltd - Berg, LLC - biOasis Technologies Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC - Diffusion Pharmaceuticals LLC - e-Therapeutics Plc - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - MEI Pharma, Inc. - NatureWise Biotech & Medicals Corporation - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Novogen Limited - Oncology Research International Limited - Oncolytics Biotech Inc. - Oncothyreon Inc. - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Sanofi - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Takeda Pharmaceutical Company Limited - Tocagen Inc. - ViraTherapeutics GmbH - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/2w...ain_cancer
ONCY: 0.33 (-0.02), PFE: 34.68 (-0.12), SPPI: 5.29 (-0.02), BMY: 56.76 (-0.63), STML: 8.15 (-0.03), ONTY: 1.21 (+0.02), NKTR: 18.11 (+0.26), MEIP: 1.74 (-0.05), ATNM: 1.76 (-0.04), ABBV: 64.03 (-0.07), EXEL: 11.35 (+0.20), NVS: 78.27 (-0.50)
Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without Brain Metastases at the San Antonio Breast Cancer Symposium
GlobeNewswire - Tue Dec 08, 3:05PM CST
Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced updated data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of HER2-positive metastatic breast cancer. The data will be the subject of two presentations at the San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.
ONTY: 1.21 (+0.02)
Here's Why Oncothyreon's Shares Pushed Higher in November
George Budwell, The Motley Fool - Motley Fool - Tue Dec 08, 2:11PM CST
Source: Pixabay What : Shares of Oncothyreon , a clinical-stage biotech developing therapies to treat cancer, rose by more than 9% in November, according to data provided by S&P Capital IQ . The catalyst driving the biotech's shares higher...
ONTY: 1.21 (+0.02), ARRY: 3.52 (+0.09)
Oncothyreon Announces Webcast to Review Updated Clinical Data on ONT-380 in HER2-Positive Breast Cancer Patients
GlobeNewswire - Wed Dec 02, 7:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced that it will conduct a conference call on Tuesday, December 8, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss new clinical data from ongoing clinical trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of metastatic breast cancer. The data, which include additional and updated clinical trial data on ONT-380 for the treatment of patients with HER2-positive metastatic breast cancer, as well as an analysis of patients who suffer from central nervous system (CNS) metastases, are slated for presentation during the San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.
ONTY: 1.21 (+0.02)
Oncothyreon to Present Updated Data on ONT-380 for the Treatment of HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium
GlobeNewswire - Mon Nov 16, 7:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of oncology products that can improve the lives and outcomes of patients, today announced that data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of metastatic breast cancer, will be presented at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.
ONTY: 1.21 (+0.02)
Oncothyreon Announces Corporate Name Change to Cascadian Therapeutics (NASDAQ: CASC)
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced that the Company is changing its name to Cascadian Therapeutics, Inc. and will trade on the NASDAQ Global Select Market under the new ticker symbol "CASC," effective at market open on June 9, 2016.
CASC: 1.12 (-0.03), ONTY: 1.21 (+0.02)
Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 in HER2+ Metastatic Breast Cancer at ASCO
GlobeNewswire - Sun Jun 05, 8:00AM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced the presentation of clinical data on its lead product candidate, ONT-380, at the 52 Annual Meeting of the American Society of Clinical Oncology (ASCO). ONT-380 is a highly selective small molecule HER2 inhibitor being developed in combination to treat HER2+ advanced or metastatic breast cancer.
ONTY: 1.21 (+0.02)
Oncothyreon reports 1Q loss
Automated Insights - Mon May 09, 3:19PM CDT
SEATTLE (AP) _ Oncothyreon Inc. (ONTY) on Monday reported a loss of $12.9 million in its first quarter.
ONTY: 1.21 (+0.02)
Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update
GlobeNewswire - Mon May 09, 3:02PM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the quarter ended March 31, 2016.
ONTY: 1.21 (+0.02)
Oncothyreon (ONTY) Catches Eye: Stock Moves 11.6% Higher
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 3:31AM CDT
Oncothyreon Inc (ONTY) shares rose almost 12% in the last trading session.
ANIK: 47.94 (+0.70), ONTY: 1.21 (+0.02)
Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:00AM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced the presentation of data highlighting the preclinical development of orally bioavailable, potent and selective checkpoint kinase 1 (Chk1) inhibitors. Results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.
ONTY: 1.21 (+0.02)
Oncothyreon Appoints Scott D. Myers Chief Executive Officer
GlobeNewswire - Tue Mar 29, 7:00AM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products to improve the lives and outcomes of patients with cancer, today announced the appointment of Scott D. Myers as President, Chief Executive Officer and a member of the Board of Directors, effective April 4, 2016.
ONTY: 1.21 (+0.02)
Endometrial Cancer - Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66589/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Endometrial Cancer Overview - Therapeutics Development - Pipeline Products for Endometrial Cancer - Overview - Pipeline Products for Endometrial Cancer - Comparative Analysis - Endometrial Cancer - Therapeutics under Development by Companies - Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes - Endometrial Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Endometrial Cancer - Products under Development by Companies - Endometrial Cancer - Products under Investigation by Universities/Institutes - Endometrial Cancer - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BeiGene(Beijing) Co.,Ltd - Boehringer Ingelheim GmbH - Cellceutix Corporation - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Pharmsynthez - Puma Biotechnology, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/s6...ndometrial
INCY: 80.81 (-0.29), IMGN: 2.80 (-0.01), ARQL: 1.40 (-0.08), LLY: 77.23 (-0.52), GSK: 42.98 (-0.48), ONTY: 1.21 (+0.02), MDVN: 80.93 (+0.37), MRK: 62.90 (+0.11), AZN: 32.60 (-0.21), AVEO: 0.91 (-0.02), GALE: 0.39 (-0.01), PBYI: 58.71 (-0.44), NVS: 78.27 (-0.50), KPTI: 11.10 (+1.15), XLRN: 30.25 (+0.24), EXEL: 11.35 (+0.20)
Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. as Interim CEO and Expands Board With Additions of Mark Lampert and Gwen Fyfe, M.D.
GlobeNewswire - Mon Jan 11, 7:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced that Robert L. Kirkman, M.D., has retired as president and CEO and as a member of the Board of Directors, effective January 11, 2016. Oncothyreon's Board of Directors has appointed Christopher S. Henney, Ph.D., D.Sc., the company's chairman, to serve as interim CEO while the company conducts a comprehensive search for a new CEO.
ONTY: 1.21 (+0.02)
Is Oncothyreon (ONTY) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Thu Dec 31, 7:31AM CST
Oncothyreon is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
ONTY: 1.21 (+0.02)
Where Investors Are Going - Complementary Research on Crocs, Oncothyreon, Nimble Storage and Rexnord
ACCESSWIRE - Mon Dec 21, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Crocs Inc. (NASDAQ: CROX), Oncothyreon Inc. (NASDAQ: ONTY), Nimble Storage Inc. (NYSE: NMBL) and Rexnord Corp. (NYSE: RXN). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CROX: 8.49 (-0.15), NMBL: 8.18 (-0.04), RXN: 21.74 (-0.37), ONTY: 1.21 (+0.02)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
BusinessWire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 0.34 (unch), TSRO: 84.35 (-0.34), CTMX: 11.72 (-0.01), NK: 8.04 (-0.05), CNCR: 24.03 (-0.05), SRNE: 6.76 (+0.10), XNCR: 21.43 (+0.30), ONTY: 1.21 (+0.02), CYAD: 22.48 (+0.48)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Fri Dec 11, 8:51AM CST
NEW YORK, NY / ACCESSWIRE / December 11, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
EYES: 3.36 (+0.01), PBMD: 0.85 (-0.02), CGEN: 7.05 (+0.02), ONTY: 1.21 (+0.02)
Timing is Crucial, Upside Analysis - Analyst Reports on YRC Worldwide, Crocs, Oncothyreon and Nimble Storage
ACCESSWIRE - Thu Dec 10, 9:55AM CST
NEW YORK, NY / ACCESSWIRE / December 10, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: YRC Worldwide Inc. (NASDAQ: YRCW), Crocs Inc. (NASDAQ: CROX), Oncothyreon Inc. (NASDAQ: ONTY) and Nimble Storage Inc. (NYSE: NMBL). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CROX: 8.49 (-0.15), NMBL: 8.18 (-0.04), ONTY: 1.21 (+0.02), YRCW: 11.58 (-0.01)
Oncothyreon Inc (USA) Plunges on Confusing Data
Brian Orelli, The Motley Fool - Motley Fool - Wed Dec 09, 12:58PM CST
What: Oncothyreon is down 30% at 1:30 p.m. EST after announcing updated data from its ongoing trials testing ONT-380 in patients with breast cancer yesterday. So what: From the stock move, you'd think the data was clearly negative, but it may...
ONTY: 1.21 (+0.02)
Global Brain Cancer Therapeutics Pipeline Review, H2 2015
M2 - Wed Dec 09, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wpxrw/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - AngioChem Inc. - Arrien Pharmaceuticals, LLC - BeiGene(Beijing) Co.,Ltd - Berg, LLC - biOasis Technologies Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC - Diffusion Pharmaceuticals LLC - e-Therapeutics Plc - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - MEI Pharma, Inc. - NatureWise Biotech & Medicals Corporation - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Novogen Limited - Oncology Research International Limited - Oncolytics Biotech Inc. - Oncothyreon Inc. - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Sanofi - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Takeda Pharmaceutical Company Limited - Tocagen Inc. - ViraTherapeutics GmbH - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/2w...ain_cancer
ONCY: 0.33 (-0.02), PFE: 34.68 (-0.12), SPPI: 5.29 (-0.02), BMY: 56.76 (-0.63), STML: 8.15 (-0.03), ONTY: 1.21 (+0.02), NKTR: 18.11 (+0.26), MEIP: 1.74 (-0.05), ATNM: 1.76 (-0.04), ABBV: 64.03 (-0.07), EXEL: 11.35 (+0.20), NVS: 78.27 (-0.50)
Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without Brain Metastases at the San Antonio Breast Cancer Symposium
GlobeNewswire - Tue Dec 08, 3:05PM CST
Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced updated data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of HER2-positive metastatic breast cancer. The data will be the subject of two presentations at the San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.
ONTY: 1.21 (+0.02)
Here's Why Oncothyreon's Shares Pushed Higher in November
George Budwell, The Motley Fool - Motley Fool - Tue Dec 08, 2:11PM CST
Source: Pixabay What : Shares of Oncothyreon , a clinical-stage biotech developing therapies to treat cancer, rose by more than 9% in November, according to data provided by S&P Capital IQ . The catalyst driving the biotech's shares higher...
ONTY: 1.21 (+0.02), ARRY: 3.52 (+0.09)
Oncothyreon Announces Webcast to Review Updated Clinical Data on ONT-380 in HER2-Positive Breast Cancer Patients
GlobeNewswire - Wed Dec 02, 7:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced that it will conduct a conference call on Tuesday, December 8, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss new clinical data from ongoing clinical trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of metastatic breast cancer. The data, which include additional and updated clinical trial data on ONT-380 for the treatment of patients with HER2-positive metastatic breast cancer, as well as an analysis of patients who suffer from central nervous system (CNS) metastases, are slated for presentation during the San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.
ONTY: 1.21 (+0.02)
Oncothyreon to Present Updated Data on ONT-380 for the Treatment of HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium
GlobeNewswire - Mon Nov 16, 7:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of oncology products that can improve the lives and outcomes of patients, today announced that data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of metastatic breast cancer, will be presented at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.
ONTY: 1.21 (+0.02)
